Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

EHA 2022 | Looking forward to EHA 2022: updates in multiple myeloma

Kwee Yong • 14 May 2022
EHA 2022
Multiple Myeloma

Kwee Yong, PhD, FRCP, FRCPath, University College London, London, UK, briefly highlights some of the exciting topics to be discussed in the field of myeloma at EHA 2022, including updates in immunotherapies and treatment approaches, and clinical trial data. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.

More from Kwee Yong

Highlights from IMS 2025: progress in the understanding and treatment of precursor conditions
2:24
Highlights from IMS 2025: progress in the understanding and treatment of precursor conditions
Kwee Yong • 19 Sep 2025
COSMOS: studying the biology of SMM through longitudinal monitoring of patients
0:55
COSMOS: studying the biology of SMM through longitudinal monitoring of patients
Kwee Yong • 27 Sep 2024
The biological and psychological uncertainties in precursor disease
3:34
The biological and psychological uncertainties in precursor disease
Kwee Yong • 27 Sep 2024
The future of managing precursor conditions
1:05
The future of managing precursor conditions
Kwee Yong • 27 Sep 2024

Related Videos

Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
4:32
Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
Kwee Yong • 18 Dec 2025
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
3:36
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
Kwee Yong • 7 Dec 2025
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
3:11
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
Kwee Yong • 7 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
Kwee Yong • 15 Dec 2025
The content of VJHemOnc is intended for healthcare professionals